Not sure if this has been posted before?
I found it on the KZIA thread at yahoo, it was posted by someone called Mark six days ago.
https://alphastocknews.com/biotech-stocks-to-buy-as-2020-comes-to-a-close/4830/Technological innovation has changed our lives in many ways. Today, we can video chat with friends on the other side of the world, build a business with nothing more than a computer, and fry food with little-to-no oil.
Technological innovation is found in just about anything we do.
However, one area its power is often discounted is in medicine. Today, various types of cancer that were once death sentences are now treatable, AIDS is a manageable condition, and hepatitis C can be cured.
Thanks to technological innovation, we’re living longer, healthier lives.
However, there are still plenty of ailments that remain a mystery to the medical community. While we learn more about these conditions every day, patients with Parkinson’s disease, glioblastoma, and several other ailments are met with few treatment options. Moreover, these options largely lack efficacy.
This has led to a wave of biotechnology companies racing to find solutions to the world’s remaining conditions that are met with few, often ineffective treatment options. When these solutions are found, the opportunities are tremendous.
Just look at Gilead Sciences. In the year 2000, the stock traded at well under $2 per share as it worked to develop a cure for Hepatitis C. After developing and commercializing a cure in 2015, GILD stock climbed to all-time highs nearly $120 per share.
Ultimately, when small biotech companies have a breakthrough in a large market, gains are all-but a guarantee. So, where do those opportunities lie in the stock market today? Some of my favorite companies that are paving the way to solutions to some of the world’s most pressing medical conditions include:
Kazia Therapeutics Ltd (NASDAQ: KZIA)
Kazia Therapeutics is an oncology-focused biotech stock that has garnered quite a bit of attention from the investing community as of late. The company has two key treatment candidates under development, CDC-0084, being developed as a potential option for patients with glioblastoma, and Cantrixil, under development as a potential option for patients with ovarian cancer.
Most recently, KZIA presented compelling data from its CDC-0084 candidate at the Society for Neuro-Oncology (SNO) Annual Meeting. The interim data from the Phase II clinical study of the candidate in glioblastoma proved to be promising from a safety, tolerability, and efficacy standpoint.
Most importantly, the interim analysis resulted in a progression-free survival (PFS) rate of 8.4 months and a median overall survival (OS) rate of 17.5 months. Temozolomide, the existing standard of care comes with a PFS of 5.3 months and an OS of 12.7 months. Moreover, given the fact that the trial is still ongoing, final PFS and OS data is not yet available, and will likely be higher than the current data being reported.
The company’s Cantrixil is resulting in similarly exciting data in early-stage clinical trials.
These markets are massive, the glioblastoma and ovarian cancer markets are expected to grow to be worth more than $3 billion and more than $6 billion per year, respectively. With KZIA stock trading with the pennies, tapping into either of these markets, even if the company only gets a small sliver of either of these markets, would lead to compelling returns, making KZIA stock one to watch closely.
